Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$29.76 USD
-1.21 (-3.91%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $29.00 -0.76 (-2.55%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.76 USD
-1.21 (-3.91%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $29.00 -0.76 (-2.55%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Zacks News
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Akero Therapeutics, Inc. (AKRO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AKRO) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Akero Therapeutics
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Akero Therapeutics (AKRO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AKRO) Outperforming Other Medical Stocks This Year?
Akero Therapeutics Inc (AKRO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Akero Therapeutics Inc (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Akero Therapeutics, Inc. (AKRO) a New Buy Stock
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Akero Therapeutics (AKRO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Should You Buy Akero Therapeutics (AKRO) Ahead of Earnings?
by Zacks Equity Research
Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.